TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34265388
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of PBSCs plus HA after arthroscopic subchondral drilling
Study: 32814506
Drug: GLU (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU (1.2 g·min‐1 dextrose alone)
Study: 32814506
Drug: GLU+CAL (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU+CAL (1.2 g·min‐1 dextrose with 2000 mg calcium)
Study: 35100594
Drug: Tamsulosin HCL
Normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin HCL 0.4 mg cap + diclofenac Na 100 mg tab (to be taken only during colic episodes)
Study: 35100594
Drug: Diclofenac Na
Normalized name: DICLOFENAC NA 1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac Na 100 mg tab only (to be taken only during colic episodes)
Study: 36054131
Drug: Dairy milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy milk (DM) - consumed twice daily (30g protein/day)
Study: 33569814
Drug: Control (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (monthly paper-based questionnaire)
Study: 33211921
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement with calcium (200 mg daily), vitamin D3 (600 IU), and vitamin B6 (2 mg) for 12 months in group 1.
Study: 33211921
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement with calcium (200 mg daily), vitamin D3 (600 IU), and vitamin B6 (2 mg) for 12 months in group 2.
Study: 33211921
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dietary supplement) in group 3.
Study: 32752932
Drug: M207 3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: M207 3.8 mg
Study: 35902887
Drug: Brolucizumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab (6 mg/50 µL)
Study: 35902887
Drug: Aflibercept (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2 mg/50 µL)
Study: 32758299
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m2 (arm B)
Study: 32758299
Drug: nab-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 100 mg/m2 (arm A)
Study: 35867857
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (n=39) with additional interventions: local anesthetic infiltration, IV dexmedetomidine, IV ketamine, additional IV dexamethasone, and repeated adductor canal block injections
Study: 35867857
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=39) with standard multimodal analgesic regimen
Study: 33619550
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab and standard chemotherapy
Study: 33619550
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus trastuzumab and standard chemotherapy
Study: 32228427
Drug: Chamomile oil
Normalized name: chamomile oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile oil inhalation
Study: 32199656
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg/kg
Study: 38388189
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day
Study: 33774594
Drug: Methylprednisolone (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1g administered intravenously upon induction of anaesthesia)
Study: 32867852
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) plus standard personal protective equipment (PPE) - 800mg loading dose on day of randomization (two 400mg doses 12 hours apart), followed by 400mg once a week for 12 weeks.
Study: 33955162
Drug: 105 mg
Normalized name: menthol 105 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg edaravone oral suspension
Study: 32321450
Drug: Sodium bicarbonate,
Normalized name: Sodium Bicarbonate, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium bicarbonate, Sodium-potassium citrate, Standard therapy
Study: 36379437
Drug: Alcohol Telemedicine
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol Telemedicine Consult (ATC) Service, including alcohol pharmacotherapy and SBIRT delivered by clinical pharmacists
Study: 37505258
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy (RRT)
Study: 33066081
Drug: n‐3 PUFA‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA‐enriched hen eggs (two eggs per day, for three weeks, total of approximately 407 mg/day n‐3 PUFAs)
Study: 33066081
Drug: Regular eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular eggs (two eggs per day for three weeks, total of approximately 75 mg/day n‐3 PUFAs)
Study: 33753956
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg
Study: 32203892
Drug: CGX 1
Normalized name: CGX-1321
DrugBank: CGX-1321 (DB17491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGX 1 g
Study: 32203892
Drug: CGX 2
Normalized name: CGX-1321
DrugBank: CGX-1321 (DB17491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGX 2 g
Study: 32203892
Drug: CGX 1
Normalized name: CGX-1321
DrugBank: CGX-1321 (DB17491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGX 1 g (without antiviral use)
Study: 39217565
Drug: Semaglutide 2.4
Normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 2.4 mg once weekly
Study: 35439567
Drug: Semaglutide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide plus cilofexor 30 mg
Study: 35439567
Drug: Semaglutide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide plus cilofexor 100 mg
Study: 35439567
Drug: Semaglutide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide plus firsocostat 20 mg
Study: 35439567
Drug: Semaglutide, cilofexor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide, cilofexor 30 mg and firsocostat
Study: 33704466
Drug: OJ with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OJ with 5 g fiber from OP (OPF)
Study: 33536047
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of IV tranexamic acid (TXA) at admission
Study: 35112378
Drug: Intravenous tanezumab
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tanezumab (2.5–20 mg every 8 weeks for up to 56 weeks)
Study: 35112378
Drug: Treatment-emergent anti-drug
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent anti-drug antibodies (TE ADA)
Study: 33012216
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (PRO; 60 g/day)
Study: 36477706
Drug: Sugammadex 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 0.5 mg/kg
Study: 33268476
Drug: NSAIDs (non-steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (non-steroidal anti-inflammatory drugs) as a strong opioid adjunct
Study: 35889835
Drug: Flaxseed supplementation
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed supplementation (28 g/day) for 10 weeks in group 1 (lean patients with severe dyslipidaemia)
Study: 35889835
Drug: Flaxseed supplementation
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed supplementation (28 g/day) for 10 weeks in group 2 (obese patients with mild dyslipidaemia)
Study: 35889835
Drug: Flaxseed supplementation
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed supplementation (28 g/day) for both groups
Study: 36167574
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia with propofol
Study: 33126873
Drug: Standard Occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Occupational Therapy (SOT)
Study: 33105036
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg
Study: 36069480
Drug: Implant Surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant Surface Culture (ISC)
Study: 32699909
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (two cycles of methotrexate, doxorubicin, vinblastine, and cisplatin) followed by radical cystectomy
Study: 36529052
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment
Study: 32274986
Drug: Hollow fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hollow fiber ultrafilter (HFU) distributed to intervention households, used for household water treatment over a 1-year period.
Study: 616330511
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7vPCV) in a 0-1-2 month schedule
Study: 616330511
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7vPCV) recipients
Study: 39453837
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg once daily)
Study: 33989338
Drug: Walking behavior
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Walking behavior change (daily step count)
Study: 34951503
Drug: Groupwise Autonomy
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groupwise Autonomy Enhancing Treatment (AET)
Study: 34951503
Drug: Groupwise Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groupwise Cognitive Behavioral Therapy (CBT)
Study: 32387472
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (FOLINORAL®) 5 mg twice daily
Study: 38862179
Drug: Aspirin monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin monotherapy (100 mg once daily)
Study: 34989804
Drug: Aflibercept (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2.0 mg/0.05 mL)
Study: 32056817
Drug: Pranayama breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranayama breathing technique for 20 min once daily for 1 month
Study: 34237184
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise program (same exercises at home on their own with weekly calls)
Study: 33307785
Drug: Empagliflozin (10/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10/25 mg)
Study: 35641166
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham treatment)
Study: 34301646
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (control)
Study: 33070770
Drug: Betamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (12 mg/kg/BW twice, intramuscularly)
Study: 32393387
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.125 M l-glutamic acid
Study: 32393387
Drug: Saline (1.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1.65 mL/kg of body weight per hour)
Study: 34562648
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser therapy
Study: 35841189
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of alcohol (MED)
Study: 35841189
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alcohol (HIGH)
Study: 33565706
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g erythritol
Study: 33755176
Drug: Preemptive antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive antiviral therapy (PET) with valganciclovir
Study: 616930567
Drug: HAS combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAS combined therapy with vinorelbine-based chemotherapy
Study: 34124972
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for insomnia and pain (CBTi.p., N = 18)
Study: 32454191
Drug: 3-Dimensional Conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-Dimensional Conformal Radiation Therapy (3DCRT)
Study: 39357788
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Radiation Therapy (IMRT)
Study: 37222189
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy
Study: 36054143
Drug: Moxifloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (800 mg/day for four days)
Study: 33028084
Drug: Adjuvant sunitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off)
Study: 33041039
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of 1:1 fish:flaxseed oil blend
Study: 33041039
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of 1:1 fish:flaxseed oil blend with 200 mg of α‐tocopherol
Study: 34613358
Drug: Vasopressin and
Normalized name: Vasopressin and analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin and steroids
Study: 34549372
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral treatment (FBT)
Study: 35297385
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate administration in the French dataset (1234 patients, 450 matched)
Study: 35297385
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate administration in the North-American dataset (4902 patients, 1238 matched)
Study: 34848523
Drug: Oestradiol cypionate
Normalized name: Estradiol Cypionate
DrugBank: Estradiol cypionate (DB13954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol cypionate intramuscular (IM) and micronised progesterone oral (PO), in addition to standard of care (SOC)
Study: 32634068
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 35373585
Drug: Bosentan (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (125 mg, twice per day for 3 days)
Study: 34986562
Drug: Lead toxicity
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead toxicity at 400 mg kg‐1
Study: 34986562
Drug: Lead toxicity
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead toxicity at 1200 mg kg‐1
Study: 34986562
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg kg‐1 lead)
Study: 32831969
Drug: Conversational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversational therapy through VR
Study: 37464404
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT)
Study: 34938292
Drug: Chemotherapy on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy on day 1 and toripalimab on day 3 (experimental group)
Study: 34938292
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and toripalimab on day 1 (control group)
Study: 35590102
Drug: Transcanalicular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcanalicular laser dacryocystorhinostomy (TCL‐DCR) with endonasal augmentation after 10 days (Group 2)
Study: 34853932
Drug: Topical aloe
Normalized name: Alo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aloe vera extract gel applied thrice daily for 2 months
Study: 34853932
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 980 nm twice weekly for 2 months
Study: 35412220
Drug: AMG 986
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 986 tablet formulation
Study: 35412220
Drug: AMG 986
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 986 capsule formulation
Study: 32949918
Drug: High-protein meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein meal (HP; 30 g protein, 17 g fat, 52 g carbohydrate)
Study: 32949918
Drug: Low-protein meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein meal (LP; 13 g protein, 25 g fat, 54 g carbohydrate)
Study: 35980648
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (silver ion alginate, hydrocolloid dressing, foam dressing)
Study: 34382590
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection combined with mouth opening training for 2 years
Study: 34382590
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of Salvia miltiorrhiza and triamcinolone acetonide, once a week, 8 times a course
Study: 35764955
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg AEO BID (Long COVID)
Study: 35764955
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg AEO (Long COVID)
Study: 35964170
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) therapy (15 sessions)
Study: 35964170
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) (9 sessions)
Study: 35818187
Drug: Pelvic IMRT
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic IMRT in combination with chemotherapy (Taxol and Carboplatin)
Study: 35818187
Drug: 3D-CRT in
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-CRT in combination with chemotherapy (Taxol and Carboplatin)
Study: 35218006
Drug: Telephone-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive behavioral therapy (Tele-CBT)
Study: 32956551
Drug: DBBM-CM (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBBM-CM (without immediate implant placement)
Study: 32956551
Drug: IMPL/DBBM-CM (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPL/DBBM-CM (with immediate implant placement)
Study: 35840087
Drug: Ixazomib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib (3 mg, days 1, 8, 15)
Study: 34369940
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine exposure (25 mL rinsed four times a day during bleaching)
Study: 33565206
Drug: Mesenchymal stromal
Normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stromal cell (MSC) therapy with early tacrolimus withdrawal
Study: 33745379
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IV-PCA)
Study: 33433720
Drug: Isotretinoin 20
Normalized name: isotretinoin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 20 mg/daily + cryotherapy
Study: 32880220
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills and patches
Study: 34601163
Drug: Periarticular multidrug
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular multidrug injection (PMDI)
Study: 34325579
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily exercise including radio gymnastics and Jianxincao)
Study: 32292074
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg liraglutide daily
Study: 35676450
Drug: TQ‐Z2301 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ‐Z2301 (40 mg subcutaneously every other week for 24 weeks)
Study: 32067149
Drug: Low-dose droperidol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose droperidol (median dose 21 µg/kg)
Study: 33244559
Drug: Encouragement to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encouragement to spend time outdoors for 20-30 minutes daily for two months during summer
Study: 34651606
Drug: Islatravir 5
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 5 mg, once daily for 42 days
Study: 34651606
Drug: Islatravir 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 0.25 mg, once daily for 28 days
Study: 34651606
Drug: Islatravir 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 0.75 mg, once daily for 28 days
Study: 34651606
Drug: Islatravir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir (all doses)
Study: 35572990
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy (EIS)